MN HF4582

Prohibits prior authorization requirements for atypical antipsychotic drugs prescribed for mental illness treatment if the drug is approved by the FDA for treating mental illness, effective January 1, 2023.

Removes prior authorization barriers for brand-name antipsychotic medications that were part of a patient's course of treatment or initially prescribed before July 1, 2003.

Requires the commissioner to automatically grant prior authorization for 60 days for brand-name mental illness drugs when a generic equivalent becomes available, provided the brand drug was part of the patient's treatment.

Amends provisions for pediatric antipsychotic and attention deficit medications to require collaborative psychiatric consultation and prior authorization for high-dose regimens, off-label use, or when multiple prescribers are involved, with exceptions for stabilized patients or children in crisis.

Applies to Minnesota's medical assistance (Medicaid) and MinnesotaCare programs and requires compliance with existing managed care prior authorization standards.